• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

August 2, 2021
Company Drug/Device Medical Condition Status
Alzamend Neuro AL001 dementia related to mild, moderate and severe cognitive impairment associated with Alzheimer’s disease IND approved by the FDA
Kronos Bio lanraplenib relapsed/refractory and newly diagnosed acute myeloid leukemia IND approved by the FDA
NeoImmuneTech NT-I7 (efineptakin alfa) Kaposi sarcoma in patients with or without HIV infection IND approved by the FDA
I-Mab efineptakin alfa advanced solid tumors IND approved by the Center for Drug Evaluation of the China National Medical Products Administration for a phase 2 trial
Arcturus Therapeutics ARCT-810 ornithine transcarbamylase deficiency clinical trial authorized by the UK Health Research Authority
Synchron Stentrodemotor neuroprosthesis severe paralysis Investigational Device Exemption approved by the FDA
Clarity Pharmaceuticals 64/67Cu SAR-bisPSMA theranostic identification and treatment of metastatic castrate-resistant prostate cancer initiation of phase 1 trial
Disc Medicine DISC-0974 anemia of inflammation initiation of phase 1 trial
Mersana Therapeutics upifitamab rilsodotin (XMT-1536) platinum-sensitive ovarian cancer initiation of phase 1 trial
Karyopharm XPOVIO in combination with Jakafi patients with treatment-naïve myelofibrosis initiation of phase 1/2 trial
MediWound MW005 low-risk basal-cell carcinoma initiation of phase 1/2 trial
XyloCor Therapeutics XC001 (encoberminogene rezmadenovec) refractory angina initiation of phase 2 portion of phase 1/2 trial
HutchMed

AstraZeneca
Orpathys (savolitinib) advanced or metastatic MET-amplified gastric cancer or adenocarcinoma of the gastroesophageal junction initiation of phase 2 trial
Karyopharm XPOVIO in combination with Keytruda locally advanced or metastatic melanoma that is resistant to initial checkpoint inhibitor therapy initiation of phase 2 trial
AbbVie Dalvance (dalbavancin) acute bacterial skin and skin structure infections in pediatric patients from birth approved by the FDA for expanded indication
AstraZeneca Bydureon BCise (exenatide extended-release) type 2 diabetes in children 10 years of age and older approved by the FDA for expanded indication
Merck Keytruda high-risk early-stage triple-negative breast cancer approved by the FDA for new indication
BeiGene Brukinsa (zanubrutinib) mantle-cell lymphoma approved in Canada

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing